Verizon Communications Inc
Change company Symbol lookup
Select an option...
VZ Verizon Communications Inc
KRTX Karuna Therapeutics Inc
SNSE Sensei Biotherapeutics Inc
ALGS Aligos Therapeutics Inc
SRRA Sierra Oncology Inc
ATOS Atossa Therapeutics Inc
OSMT Osmotica Pharmaceuticals PLC
SAND Sandstorm Gold Ltd
GRVI Grove Inc
STON Stonemor Inc
Go

Communication Services : Diversified Telecommunication Services | Large Cap Value
Company profile

Verizon Communications Inc. is a holding company. The Company, through its subsidiaries, provides communications, information and entertainment products and services to consumers, businesses and governmental agencies. Its reportable segments are Verizon Consumer Group and Verizon Business Group. Its Consumer segment provides wireless and wireline communications services. Its wireless services are provided across wireless networks in the United States (U.S.) under the Verizon brand. Its wireline services are provided in nine states in the Mid-Atlantic and Northeastern U.S., as well as Washington D.C., over its fiber-optic network under the Fios brand and over a traditional copper-based network. Its Business segment provides wireless and wireline communications services and products, including data, video and conferencing services, security and managed network services, local and long-distance voice services and network access to deliver various Internet of Things services and products.

Price
Delayed
$50.25
Day's Change
-0.545 (-1.07%)
Bid
--
Ask
--
B/A Size
--
Day's High
50.73
Day's Low
50.15
Volume
(Average)

Today's volume of 8,300,178 shares is on pace to be in-line with VZ's 10-day average volume of 24,901,801 shares.

8,300,178

CLASS ACTION UPDATE for KPLT, SESN and SPPI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

11:40 am ET October 12, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / October 12, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

KPLT Shareholders Click Here: https://www.zlk.com/pslra-1/katapult-holdings-inc-information-request-form?prid=20342&wire=1

SESN Shareholders Click Here: https://www.zlk.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=20342&wire=1

SPPI Shareholders Click Here: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=20342&wire=1

* ADDITIONAL INFORMATION BELOW *

Image: https://www.accesswire.com/users/newswire/images/667760/Rotating-Logo.jpg

Katapult Holdings, Inc. (NASDAQ:KPLT)

KPLT Lawsuit on behalf of: investors who purchased December 18, 2020 - August 10, 2021

Lead Plaintiff Deadline : October 26, 2021

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/katapult-holdings-inc-information-request-form?prid=20342&wire=1

According to the filed complaint, during the class period, Katapult Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) despite Katapult's assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers' future buying behavior; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Sesen Bio, Inc. (NASDAQ:SESN)

SESN Lawsuit on behalf of: investors who purchased December 21, 2020 - August 17, 2021

Lead Plaintiff Deadline : October 18, 2021

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=20342&wire=1

According to the filed complaint, during the class period, Sesen Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

SPPI Lawsuit on behalf of: investors who purchased December 27, 2018 - August 5, 2021

Lead Plaintiff Deadline : November 1, 2021

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=20342&wire=1

According to the filed complaint, during the class period, Spectrum Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Eduard Korsinsky, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

SOURCE: Levi & Korsinsky, LLP

View source version on accesswire.com:

https://www.accesswire.com/667760/CLASS-ACTION-UPDATE-for-KPLT-SESN-and-SPPI-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

comtex tracking

COMTEX_395032329/2457/2021-10-12T11:40:41

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.